Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978131 | 0.83 | PTGS1 (0.63) | PTGS2PTGS1PDPK1CYP1A2CYP3A4 | |
| SCHEMBL3277337 | 0.81 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL7323665 | 0.80 | PTGS2 (0.53) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL14887387 | 0.80 | PTGS2 (0.57) | PTGS2PTGS1PDPK1CYP3A4CYP2C9 | |
| SCHEMBL8292452 | 0.79 | PTGS2 (0.86) | PTGS2PTGS1PDPK1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL31566300 | 0.79 | PTGS2 (0.56) | PTGS2PTGS1PDPK1CYP3A4CYP2C9 | |
| SCHEMBL3283975 | 0.78 | PTGS2 (0.54) | PTGS2PTGS1PDPK1CYP3A4CYP2C9 | |
| SCHEMBL1880301 | 0.78 | PTGS2 (0.51) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL1887981 | 0.78 | PTGS2 (0.51) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL7242623 | 0.77 | PTGS1 (0.64) | PTGS2PTGS1PDPK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | PTGS2 158/4885PTGS1 197/4885PDPK1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.